Discovery of a potent, nonpolyglutamatable inhibitor of glycinamide ribonucleotide transformylase

Journal of Medicinal Chemistry

Volumn 49, Issue 10, 2006, Pages 2998-3002

  DeMartino, Jessica K ^a   Hwang, Inkyu ^a   Xu, Lan ^a   Wilson, Ian A ^a   Boger, Dale L ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLIC ACID; FOLIC ACID; LOMETREXOL; METHOTREXATE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; POLYGLUTAMIC ACID; TETRAZOLE DERIVATIVE;

ARTICLE; CATALYSIS; CYTOTOXICITY; DRUG POTENCY; ENZYME INHIBITION; ENZYME SUBSTRATE; ENZYME SUBUNIT; NONHUMAN; PROTEIN EXPRESSION; PURINE SYNTHESIS; RECEPTOR DOWN REGULATION;

AMINOBUTYRIC ACIDS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PEPTIDE SYNTHASES; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; POLYGLUTAMIC ACID; PYRIMIDINONES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TETRAHYDROFOLATES; TETRAZOLES;

EID: 33646743834     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0601147     Document Type: Article

References (28)

1. Warren, L.; Buchanan, J. M. 2-Amino-N-ribosylacetamide 5′-phosphate (glycinamide ribotide) transformylase. J. Biol. Chem. 1957, 229, 1979-1992.
2. Dev, I. K.; Harvey, R. J. N10-Formyltetrahydrufolate is the formyl donor for glycinamide ribonucleotide transformylase in Escherichia coli. J. Biol. Chem. 1978, 253, 4242-4244.
3. (a) Kamatani, N.; Nelson-Rees, W. A.; Carson, D. A. Selective killing of human malignant cell lines deficient in methylthioadenosine phosphorylase, a purine metabolic enzyme. Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 1219-1223.
4. See also: (b) Hori, H.; Tran, P.; Carrera, C. J.; Hori, Y.; Rosenbach, M. D.; Carson, D. A.; Nobori, T. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells. Cancer Res. 1996, 56, 5653-5658.
5. Gordon, R. B.; Blackwell, K.; Emmerson, B. T. Synthesis of purines in human lymphoblast cells deficient in methylthioadenosine phosphorylase activity. Biochim. Biophys. Acta 1987, 927, 1-7.
6. Efferth, T.; Miyachi, H.; Drexler, H. G.; Gebhart, E. Methylthioadenosine phosphorylase as target for chemoselective treatment of T-cell acute lymphoblastic leukemic cells. Blood Cells, Mol. Dis. 2002, 28, 47-56.
7. - malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis. Mol. Pharmacol. 1997, 52, 903-911.
8. Gibbs, D.; Jackman, A.; Kirkpatrick, P. Pemetrexed disodium. Nat. Rev. Drug Discovery 2005, 4, S16-S17.
9. McCloskey, D. E.; McGuire, J. J.; Russel, C. A.; Rowan, B. G.; Bertino, J. R.; Pizzorno, G.; Mini, E. J. Decreased folypolyglutamate synthase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J. Biol. Chem. 1991, 266, 6181-6187.
10. Wang, Y.; Zhao, R.; Goldman, I. D. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line. Biochem. Pharmacol. 2003, 65, 1163-1170.
11. Laohavinij, S.; Wedge, S. R.; Lind, M. J.; Bailey, N.; Humphreys, A.; Proctor, M.; Chapman, F.; Simmons, D.; Oakley, A. A phase I clinical study of the antipurine folate lometrexol (DDATHF) given with oral folic acid. Invest. New Drugs 1996, 14, 325-335.
12. Balinska, M.; Nimec, Z.; Galivan, J. Characteristics of methotrexate polyglutamate formation in cultured hepatic cells. Arch. Biochem. Biophys. 1982, 216, 466-476.
13. Marsham, P. R.; Wardleworth, J. M.; Boyle, F. T.; Hennequin, L. F.; Kimbell, R.; Brown, M.; Jackman, A. L. Design and synthesis of potent nonpolyglutamatable quinazoline antifolate thymidylate synthase inhibitors. J. Med. Chem. 1999, 42, 3809-3820.
14. Webber, S. E.; Bleckman, T. M.; Attard, J.; Deal, J. G.; Kathardekar, V.; Welsh, K. M.; Webber, S.; Janson, C. A.; Matthews, D. A.; Smith, W. W.; Freer, S. T.; Jordan, S. R.; Bacquet, R. J.; Howland, E. F.; Booth C. L. J.; Ward, R. W.; Hermann, S. M.; White, J.; Morse, C. A.; Hilliard, J. A.; Bartlett, C. A. Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones. J. Med. Chem. 1993, 36, 733-746.
15. Itoh, F.; Yukishige, K.; Wajima, M.; Ootsu, K.; Akimoto, H. Nonglutamate type pyrrolo[2,3-d]pyrimidine antifolates. I: Synthesis and biological properties of pyrrolo[2,3-d]pyrimidine antifolates containing tetrazole congeners of glutamic acid. Chem. Pharm. Bull. 1995, 43, 230-235.
16. Kisliuk, R. L. Deaza analogues of folic acid as antitumor agents. Curr. Pharm. Des. 2003, 9, 2615-2625.
17. Antonjuk, D. J.; Boadle, D. K.; Cheung, H. T. A.; Tran, T. Q. Synthesis of monoamides of methotrexate from L-glutamic acid monoamide tert-butyl esters. J. Chem. Soc., Perkin Trans. 1 1984, 1989-2003.
18. Rosowsky, A.; Forsch, R. A.; Null, A.; Moran, R. G. 5-Deazafolate analogues with a rotationally restricted glutamate or ornithine side chain: synthesis and binding interaction with folypolyglutamate synthetase. J. Med. Chem. 1999, 42, 3510-3519.
19. δ-hemiphthaloyl- L-ornithine (PT523). J. Med. Chem. 2002, 45, 1690-1696.
20. Zhang, Y.; Desharnais, J.; Marsilje, T. H.; Li, C.; Hedrick, M. P.; Gooljarsingh, L. T.; Tavassoli, A.; Benkovic, S. J.; Olson, A. J.; Boger, D. L.; Wilson, I. A. Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-trifluoroacetyl-5,10-dideaza-acyclic- 5,6,7,8-tetrahydrofolic acid. Biochemistry 2003, 42, 6043-6056.
21. 3CO-DDACTHF analogues and derivatives as inhibitors of GAR Tfase and the de novo purine biosynthetic pathway. Bioorg. Med. Chem. 2003, 11, 4511-4521.
22. 3CO-DDACTHF. Bioorg. Med. Chem. 2005, 13, 3587-3592.
23. Demko, Z.; Sharpless, K. B. An expedient route to the tetrazole analogues of α-amino acids. Org. Lett. 2002, 4, 2525-2527.
24. Bigham, E. C.; Hodson, S. J.; Mallory, W. R.; Wilson, D.; Duch, D. S.; Smith, G. K.; Ferone, R. Synthesis and biological activity of open-chain analogues of 5,6,7,8-tetrahydrofolic acid-potential antitumor agents. J. Med Chem. 1992, 35, 1399-1410.
25. Marsilje, T. H.; Labroli, M. A.; Hedrick, M. P.; Jin, Q.; Desharnais, J.; Baker, S. J.; Gooljarsingh, L. T.; Ramcharan, J.; Tavassoli, A.; Zheng, Y.; Wilson, I. A.; Beardsley, G. P.; Benkovic, S. J.; Boger, D. L. 10-Formyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid (10-formyl-DDACTHF): A potent cytotoxic agent acting by selective inhibition of human GAR Tfase and the de novo purine biosynthetic pathway. Bioorg. Med. Chem. 2002, 10, 2739-2749.
26. Habeck, L. L.; Leitner, T. A.; Shackelford, K. A.; Gossett, L. S.; Schultz, R. M.; Andis, S. L.; Shih, C.; Grindey, G. B.; Mendelsohn, L. G. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors. Cancer Res. 1994, 54, 1021-1026.
27. This assay, as is standard, was conducted with 72 h of continuous exposure to the candidate inhibitors. It has been reported that nonpolyglutamatable antifolates may exhibit lower potency under short exposure (6 h) conditions due to rapid efflux from the cells. This was not examined with 10-12 herein. See: (a) McGuire, J. J.; Russell, C. A.; Bolanowska, W. E.; Freitag, C. M.; Jones, C. S.; Kalman, T. I. Biochemical and growth inhibition studies with methotrexate and aminopterin analogues containing a tetrazole ring in place of the γ-carboxyl group. Cancer Res. 1990, 50, 1726-1731.
28. (b) Jackman, A. L.; Kimbell, R.; Aherne, G. W.; Brunton, L.; Jansen, G.; Stephens, T. C.; Smith, M. N.; Wardleworth, J. M.; Boyle, F. T. Cellular pharmacology and in vivo activity of a new anticancer agent ZD9331: a water soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin. Cancer Res. 1997, 3, 911-921.